Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
McKinsey
AstraZeneca
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Loteprednol Etabonate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00366691 ↗ Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Completed Medical University of South Carolina Phase 4 2006-02-01 The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
NCT00420628 ↗ Pediatric Zylet Safety and Efficacy Study Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
NCT00447577 ↗ Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2007-01-01 The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
NCT00560638 ↗ Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Completed Bausch & Lomb Incorporated Phase 2 2005-11-01 This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
NCT00645671 ↗ Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery Completed Bausch & Lomb Incorporated Phase 3 2008-03-01 To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
NCT00689078 ↗ Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed ORA, Inc. Phase 4 2008-05-01 To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.
NCT00699153 ↗ Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery Completed Bausch & Lomb Incorporated Phase 3 2008-06-01 Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Loteprednol Etabonate

Condition Name

Condition Name for Loteprednol Etabonate
Intervention Trials
Pain 5
Inflammation 5
Keratoconjunctivitis Sicca 4
Dry Eye 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Loteprednol Etabonate
Intervention Trials
Inflammation 13
Cataract 9
Dry Eye Syndromes 9
Conjunctivitis 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Loteprednol Etabonate

Trials by Country

Trials by Country for Loteprednol Etabonate
Location Trials
United States 127
Korea, Republic of 2
Singapore 2
Canada 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Loteprednol Etabonate
Location Trials
California 12
New York 11
Ohio 7
Missouri 7
Massachusetts 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Loteprednol Etabonate

Clinical Trial Phase

Clinical Trial Phase for Loteprednol Etabonate
Clinical Trial Phase Trials
Phase 4 16
Phase 3 14
Phase 2 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Loteprednol Etabonate
Clinical Trial Phase Trials
Completed 40
Withdrawn 2
Recruiting 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Loteprednol Etabonate

Sponsor Name

Sponsor Name for Loteprednol Etabonate
Sponsor Trials
Bausch & Lomb Incorporated 22
Kala Pharmaceuticals, Inc. 8
Khon Kaen University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Loteprednol Etabonate
Sponsor Trials
Industry 36
Other 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Baxter
Mallinckrodt
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.